TFA THERAPEUTICS, INC. · OTCQB: RAJAF
A next-generation non-steroid anti-inflammatory drug platform
TFA Therapeutics is building an Antcin A-centered platform. Lead program TFA-01 first focuses on canine osteoarthritis while target-animal safety, CMC and regulatory work continue.
TFA-01 lead programCanine osteoarthritis | Investigational, not approved
LEAD PROGRAM
TFA-01: an investigational program for canine osteoarthritis
TFA-01 is an Antcin A-centered investigational program being advanced first for inflammation associated with canine osteoarthritis.
- Candidate molecule
- Antcin A
- Lead indication
- Canine osteoarthritis
- Development class
- Non-steroid
- Product status
- Not approved
ONE DEVELOPMENT STORY
Understand TFA-01 through one development path
TFA-01 connects molecule and rights, CMC, safety, canine OA evidence, and regulatory and commercialization work. Completing a milestone reduces a defined risk; it does not mean the product is approved or marketed.
0102030405
Molecule, mechanism & rights
Published foundation / program validation underwayPublished studies support GR/GRα-related signaling for Antcin A in defined models. TFA-01 test-article, batch and indication bridging remains underway.
Next milestoneComplete candidate test-article and batch definition and strengthen program-level pharmacology relevant to canine osteoarthritis.View progress detailsCMC & controlled supply
Source foundation in place / specifications and batch bridging underwayResearch across dozens of strains and content profiles is being connected to controlled cultivation, source selection, purification, analytics and formulation development.
Next milestoneComplete physicochemical validation of the nano-enabled clear aqueous formulation, then advance formal specifications, batch consistency and process scale-up.View progress detailsSafety & toxicology
14-day preliminary toxicology report available / formal work underwayA 14-day preliminary toxicology study in female rats is complete and a report is available to inform later study design. Target-animal safety, toxicology and residue work continues.
Next milestoneComplete subsequent formal regulatory toxicology reports and establish a program-specific safety range for the purified candidate drug substance and final product.View progress detailsCanine OA clinical development
Exploratory observation completed / formal study to be establishedThe Shanghai Pet GCP Clinical Trial Team completed a two-week exploratory observation in 15 dogs. It can inform later protocol design but does not establish efficacy.
Next milestoneComplete a standardized canine osteoarthritis study with a full protocol, prespecified endpoints and a statistical analysis plan.View progress detailsRegulatory & commercialization
Taiwan advancing / U.S. CVM planningTaiwan veterinary-drug data integration continues while the U.S. CVM path is being planned. Partnership and licensing evaluation will follow the maturity of the evidence.
Next milestoneObtain clear regulatory feedback on study design, process specifications and remaining data gaps, then form an executable submission plan.View progress detailsWHO WE ARE
Building a repeatable drug-development capability
TFA connects natural-molecule discovery, controlled cultivation, purification, clinical development, and global regulatory strategy—bringing a scarce biological resource into a platform designed for verification, continued development, and future partnerships.
Evidence before claims
We distinguish published research, company-reported preliminary data and hypotheses still to be tested.
Pharmaceutical discipline
Mechanism, safety, clinical evidence, CMC and regulatory strategy advance together.
Controlled supply at the source
Controlled cultivation, raw-material analysis and process control are being advanced toward repeatable research and manufacturing capabilities.
TFA CORPORATE FILM
TFA’s science, development and global path—in four minutes
From the research foundation for Antcin A to the five development dimensions behind TFA-01 and our public-company structure.
LEADERSHIP
Core operating team
Two co-founders directly lead corporate management and technology development.
Meet our leadershipLATEST UPDATES
Company updates
INVESTOR RELATIONS
Long-term drug value through public-market transparency
TFA Therapeutics, Inc. is an SEC-reporting foreign private issuer quoted on OTCQB under the symbol RAJAF.
Advance non-steroid anti-inflammatory drug development with TFA
We welcome conversations with animal-health companies, pharmaceutical partners, clinical networks, CMC and regulatory specialists, and long-term investors.
Contact TFA